DMTKQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DMTKQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DermTech's enterprise value is $0.00 Mil. DermTech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-86.62 Mil. Therefore, DermTech's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for DermTech's EV-to-EBITDA or its related term are showing as below:
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2025-05-23), DermTech's stock price is $1.0E-6. DermTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.700. Therefore, DermTech's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
The historical data trend for DermTech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DermTech Annual Data | |||||||||||||||||
Trend | Mar16 | Mar17 | Mar18 | Mar19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -27.86 | -17.51 | -3.37 | 0.15 | -0.60 |
DermTech Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-EBITDA | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-0.57 | -0.48 | -0.34 | -0.60 | -0.45 |
For the Diagnostics & Research subindustry, DermTech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, DermTech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DermTech's EV-to-EBITDA falls into.
DermTech's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 0.000 | / | -86.623 | |
= | 0.00 |
DermTech's current Enterprise Value is $0.00 Mil.
DermTech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DermTech (OTCPK:DMTKQ) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DermTech's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 1.0E-6 | / | -2.700 | |
= | At Loss |
DermTech's share price for today is $1.0E-6.
DermTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of DermTech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin M Sun | officer: Chief Financial Officer | 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121 |
Claudia Ibarra | officer: Chief Operating Officer | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Ramin Akhavan | officer: General Counsel | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Mark Bryan Aguillard | officer: Chief Commercial Officer | 19800 CORDILL LANE, SPICEWOOD TX 78669 |
Todd Michael Wood | officer: Chief Commercial Officer | C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008 |
Bret Christensen | director, officer: Chief Executive Officer | 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
John Dobak | director, officer: Chief Executive Officer | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Kirk Malloy | director | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Mark Christopher Capone | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Herm Rosenman | director | OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ |
Nathalie Gerschtein Keraudy | director | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Monica Tellado | director | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Enrico Picozza | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Matthew L. Posard | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
From GuruFocus
By Business Wire • 12-29-2023
By Business Wire • 04-18-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Business Wire • 03-08-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Business Wire • 02-13-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.